Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
about
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvantImmune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsCOX-2 and PGE2-dependent immunomodulation in breast cancerProstate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.Prostate cancer and inflammation: the evidence.Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancerDepletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hostsTumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells.Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoringT cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadeEpigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cellsAugmenting antitumor immune responses with epigenetic modifying agents.Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cellsElevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccinationA pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.The PCa Tumor Microenvironment.Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma.Therapeutic cancer vaccines: current status and moving forward.Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasiaConsumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patientsUp-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer.Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer.Regulatory T cells and treatment of cancer.High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patientsPromising particle-based vaccines in cancer therapy.The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent.The crosstalk: Tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts.Tumor regulatory T cells potently abrogate antitumor immunity.Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
P2860
Q24655036-6F40DC68-8D03-4154-B8DD-902DFACEC394Q26784480-266F3375-B0D7-4A52-BB19-3663D5E18564Q27003937-2D3E1250-4FB6-4D95-B1BE-C6FD807F1B7FQ33606027-B17CA4AE-D89F-4D5D-BAB8-B19DE3CB25A1Q33642321-C0BCFB34-3E46-4C18-B28F-484954B12DA9Q33703387-7CF15CBD-C558-42A4-AF93-8A00B3B6463BQ33712858-6DF94EF4-E68D-40B9-851D-496A16E8F71DQ33772479-78072769-34A4-4FE8-B7FE-BB55E06E96B1Q33849500-62C3E830-D3EE-4021-93B1-077C8C5AFB48Q34124931-2E304E5F-1AAA-4884-8BF4-47FD51186842Q34150018-A028F8A6-F452-463B-993A-1160D074D6BFQ34557531-F087EC8F-EC19-446F-A744-D7962FA6F04AQ34577158-04CE53DB-B557-43C1-A626-32A7973E55E3Q34645401-C063D949-2E7C-4CA9-A7E2-0A0D651DEAA5Q34656908-DE245409-2294-40AD-8E20-9D682ACB1FB3Q35048054-C72EB564-C7B2-43FC-A401-947FA8168EB8Q35099116-9E8C7C1D-028B-4B2C-8ADE-F94F5EA7C683Q35318562-C5C16E27-DD2E-43D6-AC95-0E4B41A812CDQ35451153-BA671796-60C0-444E-A490-BD55838E2C14Q35582228-8BF35CF1-4645-42C8-A29F-9B536597E37DQ35603143-54970223-BCDE-4C8E-840A-6688CE86C75CQ35644535-C4E15FF7-43F9-428B-A517-E2F16BF26258Q35894347-D1E33757-D48E-44C0-B281-CEF50D1510CDQ36172036-F9CCB0FD-2B41-4872-BC90-406C6E6E5938Q36249153-F33A3727-2C90-4CD7-8BDC-FBD19D48C56EQ36444022-F09FCF22-EACF-4FE1-AD8E-BE789267E09CQ36708792-E0162849-D608-454A-91CD-4CDCCD5E76BFQ36733948-D40C0B4B-7C4E-4078-9DB8-9A24D5949A04Q36964048-15ED21BB-076B-4938-BD18-93E8500671C4Q37017085-8D0076A2-E6AD-4B72-8A47-8D77907943A7Q37017101-F26BAC07-F39C-48C9-8B46-63212121B369Q37084402-BBB30F31-73DC-40DE-9269-E568BE64F887Q37085326-95629C78-6807-4B33-A2AD-E6427E5E3464Q37174953-9243ED06-CEB6-47F0-AFAF-95FC23B5091BQ37225687-9A4AAC28-282C-4B67-9287-796690DC8EC8Q37259642-9D1A3C1F-404E-40C0-A888-F9F750376025Q37262995-8291EC7E-9BC7-4F5F-B8FC-BDBB1FB9BEBAQ37267037-216DD824-A563-4C36-AE45-D32FDA457E86Q37317190-FAD73B71-6736-4B77-8BC2-FDB2EDE78774Q37390970-2CA0AEA5-8B7E-446B-88E4-9884B508687B
P2860
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Enhanced functionality of CD4+CD25
@nl
Enhanced functionality of CD4+ ...... patients with prostate cancer.
@en
type
label
Enhanced functionality of CD4+CD25
@nl
Enhanced functionality of CD4+ ...... patients with prostate cancer.
@en
prefLabel
Enhanced functionality of CD4+CD25
@nl
Enhanced functionality of CD4+ ...... patients with prostate cancer.
@en
P2093
P1476
Enhanced functionality of CD4+ ...... patients with prostate cancer.
@en
P2093
Cinzia Remondo
James L Gulley
Jeffrey Schlom
Junko Yokokawa
Kwong Y Tsang
Philip M Arlen
Vittore Cereda
P304
P356
10.1158/1078-0432.CCR-07-2056
P407
P577
2008-02-01T00:00:00Z